China

AsymBio Builds Integrated End To End Platforms To Accelerate Biopharmaceutical Development

AsymBio, a subsidiary of Asymchem Group (stock code: 002821.SZ / 6821.HK), announced that it has established integrated technology platforms span...

 February 12, 2026 | News

DIFF Biotech Secures China Clinical Approval For First Domestic Nasal Spray Influenza Vaccine

Zhejiang Difference Biological Technology Co., Ltd. (DIFF Biotech) announced that its proprietary nasal spray influenza attenuated live vaccine, DIFF-flu, ...

 February 10, 2026 | News

Everest Medicines Licenses First In Class SHPT Therapy MT1013 From Micot For China And Asia Pacific

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, a...

 February 10, 2026 | News

Eisai And Henlius Sign Exclusive Japan Commercialisation Deal For Anti PD 1 Antibody Serplulimab

Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Shanghai Henlius Biotech, Inc. (Headquarters: Shanghai, China, CEO:&nbs...

 February 10, 2026 | News

Innovent Biologics And Eli Lilly Expand Oncology And Immunology Alliance With Global Development Model

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality m...

 February 10, 2026 | News

Kelun Biotech Wins China Approval For Sacituzumab Tirumotecan In Advanced Breast Cancer

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that a new indication application for its TROP2-dir...

 February 09, 2026 | News

Delonix Bioworks Secures China IND Clearance For MenB Vaccine Candidate DX 104

 Delonix Bioworks, a clinical-stage biotechnology company developing next-generation bacterial vaccines, recently announced that its Group B...

 February 09, 2026 | News

China Approves Promega OncoMate MSI Companion Diagnostic For KEYTRUDA Therapy

The National Medical Products Administration (NMPA) has approved the OncoMate® Microsatellite Instability (MSI) Detection Kit as a Class III in vi...

 February 06, 2026 | News

PepLib Biotech Enters Global Peptide Drug Discovery And Licensing Collaboration With Eli Lilly

Zonsen PepLib Biotech Inc. (“PepLib”) announced that it has entered a global research and development (R&D) collaboration and license agree...

 February 06, 2026 | News

Everest Medicines Secures Exclusive Asia Pacific Rights To First In Class Dual Target SHPT Therapy MT1013

Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturi...

 February 06, 2026 | News

Biosion Doses First Patient In Phase 1 Trial Of Novel Anti SIRPα Antibody BSI 082

Milestone validates the clinical potential of BSI-082 as a synergistic combination partner for antibody-drug conjugates (ADCs) and reinforces Biosion's "In...

 February 05, 2026 | News

SanegeneBio Licenses RNAi Programme To Genentech In Global Deal Valued Up To USD 1.7 Billion

 SanegeneBio grants exclusive worldwide license to one of its RNAi programs to Genentech - SanegeneBio to receive $200 million up...

 February 04, 2026 | News

ACROBiosystems Deepens Global Partnering Engagement At BIOSeedin Winter Innovation Summit Ahead Of J P Morgan 2026

On January 11, as the global healthcare industry gathered in San Francisco, the BIOSeedin Winter Innovation Partnering Summit successfully conven...

 February 04, 2026 | News

ZEISS Secures NMPA Approval For ARTEVO 750 And ARTEVO 850 Ophthalmic Surgical Microscopes In China

ZEISS ARTEVO 750 and ZEISS ARTEVO 850 surgical microscopes provide ophthalmic surgeons in China with end-to-end workflow integration to improve efficiency,...

 February 04, 2026 | News


News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close